NCT07339059 2026-04-09
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
Clinical Trials
8 trialsNCT04826341 2026-03-27
A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT06801834 2026-03-19
EVOKE-SCLC-04
Gilead Sciences
Phase 3 Recruiting
NCT05633667 2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2 Recruiting
NCT06055465 2025-05-15
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
Chinese University of Hong Kong
Phase 2 Recruiting
NCT06401824 2025-05-06
Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases
Maastricht University Medical Center
Phase 2 Recruiting
NCT06431633 2025-04-10
ARIAN
Fundación GECP
Phase 3 Recruiting
NCT06667167 2025-01-17
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Shaare Zedek Medical Center
Phase 2 Recruiting